Publish in this journal
Journal Information
Vol. 6. Issue 1.
Pages 23-36 (January - February 2010)
Share
Share
Download PDF
More article options
Vol. 6. Issue 1.
Pages 23-36 (January - February 2010)
DOI: 10.1016/S2173-5743(10)70006-X
Full text access
Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis
Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
Visits
...
Jesús Tornero Molinaa, Raimon Sanmartí Salab, Vicente Rodríguez Valverdec, Emilio Martín Molad, José Luis Marenco de la Fuentee, Isidoro González Álvarof, Santiago Muñoz Fernándezg, Juan Gómez-Reino Carnotah, Luis Carreño Pérezi, Enrique Batlle Gualdaj, Alejandro Balsa Criadod, José Luis Andreuk, José María Álvaro-Graciaf, Juan Antonio Martínez Lópezf,l, Estíbaliz Loza Santamaríal,??
Corresponding author
estibaliz.loza@ser.es

Corresponding author.
a Servicio de Reumatología, Hospital General de Guadalajara, Guadalajara, Spain
b Servicio de Reumatología, Hospital Clínic i Provincial, Barcelona, Spain
c Servicio de Reumatología, Hospital Marqués de Valdecilla, Santander, Spain
d Servicio de Reumatología, Hospital La Paz, Madrid, Spain
e Servicio de Reumatología, Hospital de Valme, Sevilla, Spain
f Servicio de Reumatología, Hospital de la Princesa, Madrid, Spain
g Servicio de Reumatología, Hospital Infanta Sofía, Madrid, Spain
h Servicio de Reumatología, Hospital General de Santiago, Santiago de Compostela, A Coruña, Spain
i Servicio de Reumatología, Hospital Gregorio Marañón, Madrid, Spain
j Servicio de Reumatología, Hospital General de Alicante, Alicante, Spain
k Servicio de Reumatología, Hospital Puerta de Hierro, Madrid, Spain
l Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain
Article information
Abstract
Objective

To provide a reference to rheumatologists and to those involved in the treatment of RA who are using, or about to use biologic therapy.

Methods

Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.

Results

We have produced recommendations on the use of the seven biologic agents available for RA in our country. The objective of treatment is to achieve the remission of the disease as quickly as possible. Indications and nuances regarding the use of biologic therapy were reviewed as well as the evaluation that should be performed prior to administration and the follow up of patients undergoing this therapy.

Conclusions

We present an update on the SER recommendations for the use of biologic therapy in patients with RA.

Keywords:
Consensos
Recommendations
Guidelines
Biologic therapies
Rheumatoid arthritis
Resumen
Objetivo

Servir de referencia para reumatólogos e implicados en el tratamiento de la artritis reumatoide que vayan a utilizar o consideren la utilización de terapias biológicas en su manejo.

Métodos

Las recomendaciones se emitieron siguiendo la metodología de grupos nominales y basadas en revisiones sistemáticas. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi.

Resultados

Se realizan recomendaciones sobre el uso de los siete agentes biológicos disponibles para la artritis reumatoide en la actualidad en nuestro país. El objetivo del tratamiento es lograr la remisión de la enfermedad lo más precozmente posible. Se revisan las indicaciones y matizaciones del uso de terapias biológicas y cuál debe ser la evaluación previa y la vigilancia del paciente con estos fármacos.

Conclusiones

Se presentan las actualizaciones a las recomendaciones SER para el uso de terapias biológicas en pacientes con artritis reumatoide.

Palabras clave:
Consenso
Recomendaciones
Guías
Terapias biológicas
Artritis reumatoide
Full text is only aviable in PDF
References
[1.]
L. Carmona, J. Ballina, R. Gabriel, A. Laffon.
The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.
Ann Rheum Dis, 60 (2001), pp. 1040-1045
[2.]
L.R. Lard, H. Visser, I. Speyer, I.E. Van der Horst-Bruinsma, A.H. Zwinderman, F.C. Breedveld, et al.
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
Am J Med, 111 (2001), pp. 446-451
[3.]
V.P. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M. Uffmann, J.S. Smolen.
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
Rheumatology (Oxford), 43 (2004), pp. 906-914
[4.]
C. Grigor, H. Capell, A. Stirling, A.D. McMahon, P. Lock, R. Vallance, et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
[5.]
Y.P. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, D. Van Zeben, P.J. Kerstens, J.M. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Arthritis Rheum, 52 (2005), pp. 3381-3390
[6.]
J.S. Smolen, D. Aletaha, M. Koeller, M.H. Weisman, P. Emery.
New therapies for treatment of rheumatoid arthritis.
Lancet, 370 (2007), pp. 1861-1874
[7.]
K. Fitch, S.J. Bernstein, M.D. Aguilar, B. Burnand, J.R. LaCalle, P. Lazaro, et al.
The RAND/UCLA Appropriateness Method User's Manual.
RAND, (2001),
[8.]
V. Rodríguez-Valverde, R. Cáliz Cáliz, J.M. Álvaro-Gracia Álvaro, J.L. Marenco de la Fuente, J. Mulero Mendoza, J. Tornero Molina, et al.
III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide.
Rev Esp Reumatol, 2 (2006), pp. 52-59
[9.]
Oxford Centre for Evidence-based Medicine-Levels of Evidence (March 2009). 2009 [accessed 9/22/2009]. Available at: http://www.cebm.net/index.aspx?o=1025
[10.]
Guía de práctica clínica para el manejo de la artritis reumatoide 2007 (versión HTML completa) [accessed 9/22/2009]. Available at: http://www.ser.es/practicaClinica/GUIPCAR_2007/Menu0_Principal.php
[11.]
GUIPCAR. Principales fármacos modificadores de la enfermedad (FAME) 2007 [accessed 9/22/2009]. Available at: http://www.ser.es/practicaClinica/GUIPCAR _2007/Tablas/Tabla21.php
[12.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[13.]
M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, et al.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
N Engl J Med, 340 (1999), pp. 253-259
[14.]
P.E. Lipsky, D.M. Van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, J.R. Kalden, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1594-1602
[15.]
J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, E.C. Keystone, et al.
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1586-1593
[16.]
E.W. St Clair, D.M. Van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
Arthritis Rheum, 50 (2004), pp. 3432-3443
[17.]
F.C. Breedveld, P. Emery, E. Keystone, K. Patel, D.E. Furst, J.R. Kalden, et al.
Infliximab in active early rheumatoid arthritis.
Ann Rheum Dis, 63 (2004), pp. 149-155
[18.]
R. Sanmartí, J.A. Gómez-Puerta, J.R. Rodríguez-Cros, C. Albaladejo, J. Muñoz-Gómez, J.D. Cañete.
Etanercept en pacientes con artritis reumatoide y escasa respuesta terapéutica a infliximab.
Med Clin (Barc), 122 (2004), pp. 321-324
[19.]
D. Van der Heijde, L. Klareskog, V. Rodriguez-Valverde, C. Codreanu, H. Bolosiu, J. Melo-Gomes, et al.
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.
Arthritis Rheum, 54 (2006), pp. 1063-1074
[20.]
J.R. Kalden, C. Antoni, J.M. Alvaro-Gracia, B. Combe, P. Emery, J.M. Kremer, et al.
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 1620-1631
[21.]
B. Combe, C. Codreanu, U. Fiocco, M. Gaubitz, P.P. Geusens, T.K. Kvien, et al.
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
Ann Rheum Dis, 65 (2006), pp. 1357-1362
[22.]
B. Combe, C. Codreanu, U. Fiocco, M. Gaubitz, P.P. Geusens, T.K. Kvien, et al.
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.
Ann Rheum Dis, 68 (2009), pp. 1146-1152
[23.]
S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, L.W. Moreland, et al.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-fourweek, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 614-624
[24.]
A.A. Fitzgerald, S.A. Leclercq, A. Yan, J.E. Homik, C.A. Dinarello.
Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Arthritis Rheum, 52 (2005), pp. 1794-1803
[25.]
C.A. Dinarello.
Blocking IL-1 in systemic inflammation.
J Exp Med, 201 (2005), pp. 1355-1359
[26.]
P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, et al.
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Arthritis Rheum, 54 (2006), pp. 1390-1400
[27.]
S.B. Cohen, P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, et al.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum, 54 (2006), pp. 2793-2806
[28.]
E. Keystone, P. Emery, C.G. Peterfy, P.P. Tak, S. Cohen, M.C. Genovese, et al.
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Ann Rheum Dis, 68 (2009), pp. 216-221
[29.]
P.P. Takk, W. Rigby, A. Rubbert, C. Peterfy, R.F. Van Vollenhoven, W. Stohl, et al.
Inhibition of joint damage and improved clinical outcomes with a combination of rituximab (RTX) and methotrexate (MTX) in patients (PTS) with early active rheumatoid arthritis (RA) who are naive to MTX: arandomised active comparator placebo-controlled trial.
Ann Rheum Dis, 68 (2009), pp. 75
[30.]
J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, et al.
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
Ann Intern Med, 144 (2006), pp. 865-876
[31.]
M.C. Genovese, J.C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med, 353 (2005), pp. 1114-1123
[32.]
J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, et al.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
[33.]
M.C. Genovese, J.D. McKay, E.L. Nasonov, E.F. Mysler, N.A. Da Silva, E. Alecock, et al.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional diseasemodifying antirheumatic drug therapy study.
Arthritis Rheum, 58 (2008), pp. 2968-2980
[34.]
G. Jones, A. Sebba, J. Gu, M.B. Lowenstein, A. Calvo, J.J. Gomez-Reino, et al.
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study.
Ann Rheum Dis, (2009),
[35.]
P. Emery, E. Keystone, H.P. Tony, A. Cantagrel, R. van Vollenhoven, A. Sanchez, et al.
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Ann Rheum Dis, 67 (2008), pp. 1516-1523
[36.]
N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, et al.
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab.
Ann Rheum Dis, 66 (2007), pp. 1162-1167
[37.]
N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, J. Azuma, et al.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Mod Rheumatol, 19 (2009), pp. 12-19
[38.]
P. Emery, E. Keystone, H.P. Tony, A. Cantagrel, R.F. Vollenhoven, A. Sanchez, et al.
Tociluzumab (TCZ) rapidly and significantly improves outcomes in patients with rheumatoid arthritis (RA) who have inadequate response (IR) to TNF antagonists.
Arthritis Rheum, 58 (2008), pp. S617
[39.]
J. Esteve-Vives, E. Batlle-Gualda, A. Reig, Grupo para la Adaptacion del HAQ a la Poblacion Espanola.
Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency.
J Rheumatol, 20 (1993), pp. 2116-2122
[40.]
D.M. Van der Heijde, M. Van’t Hof, P.L. Van Riel, L.B. Van de Putte.
Development of a disease activity score based on judgment in clinical practice by rheumatologists.
J Rheumatol, 20 (1993), pp. 579-581
[41.]
D.M. Van der Heijde, M.A. Van’t Hof, P.L. Van Riel, M.A. Van Leeuwen, M.H. Van Rijswijk, L.B. Van de Putte.
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.
Ann Rheum Dis, 51 (1992), pp. 177-181
[42.]
M.L. Prevoo, M.A. Van’t Hof, H.H. Kuper, M.A. Van Leeuwen, L.B. Van de Putte, P.L. Van Riel.
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
Arthritis Rheum, 38 (1995), pp. 44-48
[43.]
J.S. Smolen, F.C. Breedveld, M.H. Schiff, J.R. Kalden, P. Emery, G. Eberl, et al.
A simplified disease activity index for rheumatoid arthritis for use in clinical practice.
Rheumatology (Oxford), 42 (2003), pp. 244-257
[44.]
D. Aletaha, J. Smolen.
The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
Clin Exp Rheumatol, 23 (2005), pp. S100-S108
[45.]
M.L. Prevoo, A.M. Van Gestel, T.H.M.A. Van, M.H. Van Rijswijk, L.B. Van de Putte, P.L. Van Riel.
Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score.
Br J Rheumatol, 35 (1996), pp. 1101-1105
[46.]
A. Balsa, L. Carmona, I. Gonzalez-Alvaro, M.A. Belmonte, X. Tena, R. Sanmarti, et al.
Value of disease activity score 28 (das28) and das28-3 compared to american college of rheumatology-defined remission in rheumatoid arthritis.
J Rheumatol, 31 (2004), pp. 40-46
[47.]
D. Aletaha, M.M. Ward, K.P. Machold, V.P. Nell, T. Stamm, J.S. Smolen.
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.
Arthritis Rheum, 52 (2005), pp. 2625-2636
[48.]
I. Castrejon, A.M. Ortiz, R. Garcia-Vicuna, J.P. Lopez-Bote, A. Humbria, L. Carmona, et al.
Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?.
Clin Exp Rheumatol, 26 (2008), pp. 769-775
[49.]
B.J. Radovits, J. Fransen, P.L. Van Riel, R.F. Laan.
Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis.
Ann Rheum Dis, 67 (2008), pp. 1127-1131
[50.]
M. Ahlmén, B. Svensson, K. Albertsson, K. Forslind, I. Hafstrom.
Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage.
Ann Rheum Dis, 69 (2009), pp. 230-233
[51.]
B.F. Leeb, P.M. Haindl, A. Maktari, T. Nothnagl, B. Rintelen.
Disease activity score-28 values differ considerably depending on patient's pain perception and sex.
J Rheumatol, 34 (2007), pp. 2382-2387
[52.]
A.M. Unruh.
Gender variations in clinical pain experience.
Pain, 65 (1996), pp. 123-167
[53.]
M.A. Quinn, P.G. Conaghan, P. Emery.
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?.
Rheumatology (Oxford), 40 (2001), pp. 1211-1220
[54.]
M. Boers.
Understanding the window of opportunity concept in early rheumatoid arthritis.
Arthritis Rheum, 48 (2003), pp. 1771-1774
[55.]
I. Gonzalez-Alvaro, M.A. Descalzo, L. Carmona.
Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort.
Arthritis Res Ther, 10 (2008), pp. R138
[56.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, et al.
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
[57.]
J.S. Smolen, D.M. Van Der Heijde, E.W. St Clair, P. Emery, J.M. Bathon, E. Keystone, et al.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Arthritis Rheum, 54 (2006), pp. 702-710
[58.]
P. Emery, F.C. Breedveld, S. Hall, P. Durez, D.J. Chang, D. Robertson, et al.
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
[59.]
R.N. Maini, P.C. Taylor, J. Szechinski, K. Pavelka, J. Broll, G. Balint, et al.
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Arthritis Rheum, 54 (2006), pp. 2817-2829
[60.]
M.C. Genovese, M. Schiff, M. Luggen, J.C. Becker, R. Aranda, J. Teng, et al.
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Ann Rheum Dis, 67 (2008), pp. 547-554
[61.]
M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J.C. Becker, E. Keystone.
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study.
Arthritis Rheum, 54 (2006), pp. 2807-2816
[62.]
M. Weinblatt, M. Schiff, A. Goldman, J. Kremer, M. Luggen, T. Li, et al.
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Ann Rheum Dis, 66 (2007), pp. 228-234
[63.]
J.S. Smolen, J. Kay, M.K. Doyle, R. Landewe, E.L. Matteson, J. Wollenhaupt, et al.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
[64.]
R.F. Vollenhoven, E. Gullstrom, S. Brannemark, L. Klareskog.
Dose escalation of infliximab in clinical practice: Data from the Stockholm TNF registry.
Arthritis Rheum, 44 (2001), pp. S82
[65.]
K. Pavelka, K. Jarosova, D. Suchy, L. Senolt, K. Chroust, L. Dusek, et al.
Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Ann Rheum Dis, 68 (2009), pp. 1285-1289
[66.]
O. Brocq, Y. Plubel, V. Breuil, C. Grisot, P. Flory, A. Mousnier, et al.
[Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
Presse Med, 31 (2002), pp. 1836-1839
[67.]
K.E. Hansen, J.P. Hildebrand, M.C. Genovese, J.J. Cush, S. Patel, D.A. Cooley, et al.
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
J Rheumatol, 31 (2004), pp. 1098-1102
[68.]
A. Finckh, A. Ciurea, L. Brulhart, D. Kyburz, B. Moller, S. Dehler, et al.
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Arthritis Rheum, 56 (2007), pp. 1417-1423
[69.]
M.F. Doran, C.S. Crowson, G.R. Pond, W.M. O’Fallon, S.E. Gabriel.
Frequency of infection in patients with rheumatoid arthritis compared with controls: a populationbased study.
Arthritis Rheum, 46 (2002), pp. 2287-2293
[70.]
E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin, F. Granath, et al.
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Arthritis Rheum, 54 (2006), pp. 692-701
[71.]
D.H. Solomon, E.W. Karlson, E.B. Rimm, C.C. Cannuscio, L.A. Mandl, J.E. Manson, et al.
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
Circulation, 107 (2003), pp. 1303-1307
[72.]
L. Carmona, J. Gómez-Reino, R. González.
Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación a 14 de enero de 2005.
Reumatol Clin, 1 (2005), pp. 95-111
[73.]
D.E. Furst, M.H. Schiff, R.M. Fleischmann, V. Strand, C.A. Birbara, D. Compagnone, et al.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
J Rheumatol, 30 (2003), pp. 2563-2571
[74.]
M.C. Genovese, J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, et al.
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Arthritis Rheum, 46 (2002), pp. 1443-1450
[75.]
A. Strangfeld, J. Listing, P. Herzer, A. Liebhaber, K. Rockwitz, C. Richter, et al.
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
JAMA, 301 (2009), pp. 737-744
[76.]
D. Khanna, M. McMahon, D.E. Furst.
Safety of tumour necrosis factor-alpha antagonists.
Drug Saf, 27 (2004), pp. 307-324
[77.]
C. Salliot, M. Dougados, L. Gossec.
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
Ann Rheum Dis, 68 (2009), pp. 25-32
[78.]
J.J. Gomez-Reino, L. Carmona, M. Angel Descalzo.
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Arthritis Rheum, 57 (2007), pp. 756-761
[79.]
J.J. Gomez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, M.D. Montero.
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Arthritis Rheum, 48 (2003), pp. 2122-2127
[80.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[81.]
A.K. Mohan, T.R. Cote, J.A. Block, A.M. Manadan, J.N. Siegel, M.M. Braun.
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
Clin Infect Dis, 39 (2004), pp. 295-299
[82.]
L. Carmona, J.J. Gomez-Reino, V. Rodriguez-Valverde, D. Montero, E. Pascual-Gomez, E.M. Mola, et al.
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Arthritis Rheum, 52 (2005), pp. 1766-1772
[83.]
L.H. Calabrese, N.N. Zein, D. Vassilopoulos, B Hepatitis.
virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
Ann Rheum Dis, 65 (2006), pp. 983-989
[84.]
F.A. Parke, J.D. Reveille.
Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
Arthritis Rheum, 51 (2004), pp. 800-804
[85.]
N.N. Zein.
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
J Hepatol, 42 (2005), pp. 315-322
[86.]
D.U. Cansu, T. Kalifoglu, C. Korkmaz.
Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
J Rheumatol, 35 (2008), pp. 421-424
[87.]
C. Ferri, G. Ferraccioli, D. Ferrari, M. Galeazzi, G. Lapadula, C. Montecucco, et al.
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
J Rheumatol, 35 (2008), pp. 1944-1949
[88.]
E.J. Cepeda, F.M. Williams, M.L. Ishimori, M.H. Weisman, J.D. Reveille.
The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Ann Rheum Dis, 67 (2008), pp. 710-712
[89.]
J.L. Kaine, A.J. Kivitz, C. Birbara, A.Y. Luo.
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
J Rheumatol, 34 (2007), pp. 272-279
[90.]
O. Elkayam, D. Caspi, T. Reitblatt, D. Charboneau, J.B. Rubins.
The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Semin Arthritis Rheum, 33 (2004), pp. 283-288
[91.]
O. Elkayam, A. Bashkin, M. Mandelboim, I. Litinsky, D. Comaheshter, D. Levartovsky, et al.
The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
Semin Arthritis Rheum, (2009),
[92.]
L.B.S. Gelinck, Y.K.O. Teng, G.F. Rimmelzwaan, B.J.F. Van Den Bemt, F.P. Kroon, J.M. Van Laar.
Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
Ann Rheum Dis, 66 (2007), pp. 1402-1403
[93.]
S. Oren, M. Mandelboim, Y. Braun-Moscovici, D. Paran, J. Ablin, I. Litinsky, et al.
Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response.
Ann Rheum Dis, 67 (2008), pp. 937-941
[94.]
C. Bibbo, J.W. Goldberg.
Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
Foot Ankle Int, 25 (2004), pp. 331-335
[95.]
S. Corrao, G. Pistone, S. Arnone, L. Calvo, R. Scaglione, G. Licata.
Safety of etanercept therapy in rheumatoid patients undergoing surgery: Preliminary report.
Clin Rheumatol, 26 (2007), pp. 1513-1515
[96.]
A.A. Den Broeder, M.C. Creemers, J. Fransen, E. De Jong, D.J. De Rooij, A. Wymenga, et al.
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
J Rheumatol, 34 (2007), pp. 689-695
[97.]
D. Wendling, J.C. Balblanc, A. Brousse, A. Lohse, G. Lehuede, P. Garbuio, et al.
Surgery in patients receiving anti-tumour necrosis factor (alpha) treatment in rheumatoid arthritis: An observational study on 50 surgical procedures.
Ann Rheum Dis, 64 (2005), pp. 1378-1379
[98.]
J.T. Giles, S.J. Bartlett, A.C. Gelber, S. Nanda, K. Fontaine, V. Ruffing, et al.
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.
Arthritis Care Res, 55 (2006), pp. 333-337
[99.]
D.L. Scott, G.H. Kingsley.
Tumor necrosis factor inhibitors for rheumatoid arthritis.
N Engl J Med, 355 (2006), pp. 704-712
[100.]
J. Sibilia, R. Westhovens.
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Clin Exp Rheumatol, 25 (2007), pp. S46-S56
[101.]
L. Abasolo, E. Judez, M.A. Descalzo, I. Gonzalez-Alvaro, J.A. Jover, L. Carmona.
Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population.
Semin Arthritis Rheum, 37 (2008), pp. 388-397
[102.]
P. Geborek, A. Bladstrom, C. Turesson, A. Gulfe, I.F. Petersson, T. Saxne, et al.
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Ann Rheum Dis, 64 (2005), pp. 699-703
[103.]
S.K. Okada, J.N. Siegel.
Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
JAMA, 296 (2006), pp. 2201-2202
[104.]
S. Setoguchi, S. Schneeweiss, J. Avorn, J.N. Katz, M.E. Weinblatt, R. Levin, et al.
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.
Am Heart J, 156 (2008), pp. 336-341
[105.]
J.R. Curtis, J.M. Kramer, C. Martin, K.G. Saag, N. Patkar, D. Shatin, et al.
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
Rheumatology (Oxford), 46 (2007), pp. 1688-1693
[106.]
L. Martin, S. Barr, F. Green, M. Fritzer.
Severe fatal cpmplications associated with infliximab therapy in rheumatoid arthritis.
J Rheumatol, 33 (2006), pp. 380
[107.]
A.J. Ostor, E.R. Chilvers, M.F. Somerville, A.Y. Lim, S.E. Lane, A.J. Crisp, et al.
Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
J Rheumatol, 33 (2006), pp. 622-628
[108.]
I. Simsek, H. Erdem, S. Pay, G. Sobaci, A. Dinc.
Optic neuritis occurring with antitumour necrosis factor alpha therapy.
Ann Rheum Dis, 66 (2007), pp. 1255-1258
[109.]
L. Bensouda-Grimaldi, D. Mulleman, J.P. Valat, E. Autret-Leca.
Adalimumabassociated multiple sclerosis.
J Rheumatol, 34 (2007), pp. 239-240
[110.]
E.C. Keystone.
Safety of biologic therapies–an update.
J Rheumatol Suppl, 74 (2005), pp. 8-12
[111.]
M. Ostensen, M. Lockshin, A. Doria, G. Valesini, P. Meroni, C. Gordon, et al.
Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs.
Rheumatology (Oxford), 47 (2008), pp. iii28-iii31
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.